SK35199A3 - Use of benzopyranols to treat neurological disorders - Google Patents

Use of benzopyranols to treat neurological disorders Download PDF

Info

Publication number: SK35199A3
Authority: SK; Slovakia
Prior art keywords: alkyl; hydrogen; amino; nitro; alkoxy
Prior art date: 1996-09-18

Application number

SK351-99A

Other languages

English (en)

Slovak (sk)

Inventor

Andrew Parsons

Mervyn Thompson

Neil Upton

John Morris Evans

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-09-18

Filing date

1997-09-15

Publication date

2000-07-11

1997-09-15 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

2000-07-11 Publication of SK35199A3 publication Critical patent/SK35199A3/sk

Links

SERVTOXIOYSDQO-UHFFFAOYSA-N 2h-chromen-2-ol Chemical class C1=CC=C2C=CC(O)OC2=C1 SERVTOXIOYSDQO-UHFFFAOYSA-N 0.000 title claims description 7
208000012902 Nervous system disease Diseases 0.000 title description 3
208000025966 Neurological disease Diseases 0.000 title description 3
208000004296 neuralgia Diseases 0.000 claims abstract description 18
238000011282 treatment Methods 0.000 claims abstract description 17
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 14
208000021722 neuropathic pain Diseases 0.000 claims abstract description 11
206010044652 trigeminal neuralgia Diseases 0.000 claims abstract description 10
208000030507 AIDS Diseases 0.000 claims abstract description 7
206010058019 Cancer Pain Diseases 0.000 claims abstract description 7
208000008238 Muscle Spasticity Diseases 0.000 claims abstract description 7
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims abstract description 7
208000009205 Tinnitus Diseases 0.000 claims abstract description 7
208000030886 Traumatic Brain injury Diseases 0.000 claims abstract description 7
206010012601 diabetes mellitus Diseases 0.000 claims abstract description 7
206010022437 insomnia Diseases 0.000 claims abstract description 7
230000001537 neural effect Effects 0.000 claims abstract description 7
208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 7
230000007971 neurological deficit Effects 0.000 claims abstract description 7
238000011321 prophylaxis Methods 0.000 claims abstract description 7
201000000980 schizophrenia Diseases 0.000 claims abstract description 7
208000019116 sleep disease Diseases 0.000 claims abstract description 7
208000018198 spasticity Diseases 0.000 claims abstract description 7
231100000886 tinnitus Toxicity 0.000 claims abstract description 7
230000009529 traumatic brain injury Effects 0.000 claims abstract description 7
206010003591 Ataxia Diseases 0.000 claims abstract description 6
208000000323 Tourette Syndrome Diseases 0.000 claims abstract description 6
201000003631 narcolepsy Diseases 0.000 claims abstract description 6
201000010099 disease Diseases 0.000 claims abstract description 5
208000026072 Motor neurone disease Diseases 0.000 claims abstract description 4
208000002193 Pain Diseases 0.000 claims abstract description 3
125000000217 alkyl group Chemical group 0.000 claims description 71
229910052739 hydrogen Inorganic materials 0.000 claims description 38
239000001257 hydrogen Substances 0.000 claims description 38
-1 perfluoro Chemical group 0.000 claims description 26
150000002431 hydrogen Chemical class 0.000 claims description 24
125000003545 alkoxy group Chemical group 0.000 claims description 17
125000004093 cyano group Chemical group *C#N 0.000 claims description 14
125000000753 cycloalkyl group Chemical group 0.000 claims description 14
229910052736 halogen Inorganic materials 0.000 claims description 14
150000002367 halogens Chemical class 0.000 claims description 14
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 14
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 13
125000003118 aryl group Chemical group 0.000 claims description 12
125000004448 alkyl carbonyl group Chemical group 0.000 claims description 10
208000035475 disorder Diseases 0.000 claims description 9
125000003710 aryl alkyl group Chemical group 0.000 claims description 8
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 8
125000001188 haloalkyl group Chemical group 0.000 claims description 8
125000001072 heteroaryl group Chemical group 0.000 claims description 8
229910052760 oxygen Inorganic materials 0.000 claims description 8
239000001301 oxygen Substances 0.000 claims description 8
150000003839 salts Chemical class 0.000 claims description 8
239000012453 solvate Substances 0.000 claims description 8
239000003814 drug Substances 0.000 claims description 7
229910052757 nitrogen Inorganic materials 0.000 claims description 7
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 6
208000023105 Huntington disease Diseases 0.000 claims description 6
206010052904 Musculoskeletal stiffness Diseases 0.000 claims description 6
125000005196 alkyl carbonyloxy group Chemical group 0.000 claims description 6
230000004064 dysfunction Effects 0.000 claims description 6
125000004356 hydroxy functional group Chemical group O* 0.000 claims description 6
230000033764 rhythmic process Effects 0.000 claims description 6
230000002123 temporal effect Effects 0.000 claims description 6
208000004371 toothache Diseases 0.000 claims description 6
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 6
239000008194 pharmaceutical composition Substances 0.000 claims description 5
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
125000003342 alkenyl group Chemical group 0.000 claims description 4
125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 4
125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 4
125000003277 amino group Chemical group 0.000 claims description 4
125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 4
125000004391 aryl sulfonyl group Chemical group 0.000 claims description 4
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 4
125000001589 carboacyl group Chemical group 0.000 claims description 4
229910052799 carbon Inorganic materials 0.000 claims description 4
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 4
125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 4
208000005264 motor neuron disease Diseases 0.000 claims description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
229910052717 sulfur Inorganic materials 0.000 claims description 4
201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims description 3
208000016620 Tourette disease Diseases 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
201000006417 multiple sclerosis Diseases 0.000 claims description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 2
125000003282 alkyl amino group Chemical group 0.000 claims description 2
125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 2
125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 2
125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 2
125000004691 alkyl thio carbonyl group Chemical group 0.000 claims description 2
125000003435 aroyl group Chemical group 0.000 claims description 2
125000005129 aryl carbonyl group Chemical group 0.000 claims description 2
125000005199 aryl carbonyloxy group Chemical group 0.000 claims description 2
125000005135 aryl sulfinyl group Chemical group 0.000 claims description 2
125000004104 aryloxy group Chemical group 0.000 claims description 2
125000004429 atom Chemical group 0.000 claims description 2
125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 2
125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 claims description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
229910052794 bromium Inorganic materials 0.000 claims description 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
239000000460 chlorine Chemical group 0.000 claims description 2
229910052801 chlorine Inorganic materials 0.000 claims description 2
125000004122 cyclic group Chemical group 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
CHNUOJQWGUIOLD-NFZZJPOKSA-N epalrestat Chemical compound C=1C=CC=CC=1\C=C(/C)\C=C1/SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-NFZZJPOKSA-N 0.000 claims description 2
229910052731 fluorine Inorganic materials 0.000 claims description 2
239000011737 fluorine Substances 0.000 claims description 2
125000004446 heteroarylalkyl group Chemical group 0.000 claims description 2
125000005223 heteroarylcarbonyl group Chemical group 0.000 claims description 2
125000005204 heteroarylcarbonyloxy group Chemical group 0.000 claims description 2
125000005553 heteroaryloxy group Chemical group 0.000 claims description 2
125000005150 heteroarylsulfinyl group Chemical group 0.000 claims description 2
125000005143 heteroarylsulfonyl group Chemical group 0.000 claims description 2
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical class C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims description 2
125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 claims description 2
239000011593 sulfur Substances 0.000 claims description 2
150000003852 triazoles Chemical class 0.000 claims description 2
208000009999 tuberous sclerosis Diseases 0.000 claims description 2
125000001153 fluoro group Chemical group F* 0.000 claims 1
229910052698 phosphorus Inorganic materials 0.000 claims 1
125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims 1
150000001562 benzopyrans Chemical class 0.000 abstract description 5
241001480592 Chlorophyllum molybdites Species 0.000 abstract description 4
206010008748 Chorea Diseases 0.000 abstract 1
208000017164 Chronobiology disease Diseases 0.000 abstract 1
208000002740 Muscle Rigidity Diseases 0.000 abstract 1
206010043220 Temporomandibular joint syndrome Diseases 0.000 abstract 1
208000012601 choreatic disease Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 description 26
239000000203 mixture Substances 0.000 description 15
238000000034 method Methods 0.000 description 10
229940125782 compound 2 Drugs 0.000 description 9
210000001715 carotid artery Anatomy 0.000 description 8
229940125904 compound 1 Drugs 0.000 description 8
230000002792 vascular Effects 0.000 description 8
230000000694 effects Effects 0.000 description 7
238000009472 formulation Methods 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
241000282326 Felis catus Species 0.000 description 5
238000001990 intravenous administration Methods 0.000 description 5
230000003276 anti-hypertensive effect Effects 0.000 description 4
229940126214 compound 3 Drugs 0.000 description 4
239000007788 liquid Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000000945 filler Substances 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
229920000609 methyl cellulose Polymers 0.000 description 3
239000001923 methylcellulose Substances 0.000 description 3
238000002156 mixing Methods 0.000 description 3
210000005036 nerve Anatomy 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
239000003826 tablet Substances 0.000 description 3
239000000080 wetting agent Substances 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
241000700159 Rattus Species 0.000 description 2
208000034189 Sclerosis Diseases 0.000 description 2
230000017531 blood circulation Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000003086 colorant Substances 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
150000002118 epoxides Chemical class 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
239000008187 granular material Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000008447 perception Effects 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000004044 response Effects 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
210000003901 trigeminal nerve Anatomy 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
206010059150 Cerebrosclerosis Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
208000004454 Hyperalgesia Diseases 0.000 description 1
208000035154 Hyperesthesia Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
206010026749 Mania Diseases 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
206010029240 Neuritis Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
208000002847 Surgical Wound Diseases 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000002730 additional effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
125000005138 alkoxysulfonyl group Chemical group 0.000 description 1
125000004685 alkoxythiocarbonyl group Chemical group 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
239000012080 ambient air Substances 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000001773 anti-convulsant effect Effects 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
229960003965 antiepileptics Drugs 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
230000008321 arterial blood flow Effects 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
210000001168 carotid artery common Anatomy 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
OJYGBLRPYBAHRT-IPQSZEQASA-N chloralose Chemical compound O1[C@H](C(Cl)(Cl)Cl)O[C@@H]2[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]21 OJYGBLRPYBAHRT-IPQSZEQASA-N 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000002662 enteric coated tablet Substances 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
125000005469 ethylenyl group Chemical group 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
210000001105 femoral artery Anatomy 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
210000000548 hind-foot Anatomy 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003978 infusion fluid Substances 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
230000002601 intratumoral effect Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000019426 modified starch Nutrition 0.000 description 1
RCLXAPJEFHPYEG-MSOLQXFVSA-N n-[(3s,4r)-6-acetyl-3-hydroxy-2,2-dimethyl-3,4-dihydrochromen-4-yl]-4-fluorobenzamide Chemical compound N([C@H]1[C@H](O)C(C)(C)OC2=CC=C(C=C21)C(=O)C)C(=O)C1=CC=C(F)C=C1 RCLXAPJEFHPYEG-MSOLQXFVSA-N 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
239000000523 sample Substances 0.000 description 1
210000003497 sciatic nerve Anatomy 0.000 description 1
238000007789 sealing Methods 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
229940032147 starch Drugs 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000009827 uniform distribution Methods 0.000 description 1
239000003981 vehicle Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyrane Compounds (AREA)

SK351-99A 1996-09-18 1997-09-15 Use of benzopyranols to treat neurological disorders SK35199A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9619492.3A GB9619492D0 (en)	1996-09-18	1996-09-18	Novel treatment
PCT/EP1997/005168 WO1998011890A1 (en)	1996-09-18	1997-09-15	Use of benzopyranols to treat neurological disorders

Publications (1)

Publication Number	Publication Date
SK35199A3 true SK35199A3 (en)	2000-07-11

Family

ID=10800127

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK351-99A SK35199A3 (en)	1996-09-18	1997-09-15	Use of benzopyranols to treat neurological disorders

Country Status (30)

Country	Link
EP (1)	EP0939630B1 (de)
JP (1)	JP2001500520A (de)
KR (1)	KR20000036184A (de)
CN (1)	CN1230885A (de)
AP (1)	AP9901473A0 (de)
AR (1)	AR008838A1 (de)
AT (1)	ATE270102T1 (de)
AU (1)	AU730465B2 (de)
BG (1)	BG103252A (de)
BR (1)	BR9712030A (de)
CA (1)	CA2266681A1 (de)
DE (1)	DE69729735T2 (de)
DZ (1)	DZ2311A1 (de)
EA (1)	EA199900306A1 (de)
ES (1)	ES2223075T3 (de)
GB (1)	GB9619492D0 (de)
HU (1)	HUP9904638A3 (de)
ID (2)	ID23175A (de)
IL (1)	IL128786A0 (de)
MA (1)	MA24321A1 (de)
NO (1)	NO991292L (de)
NZ (1)	NZ334271A (de)
OA (1)	OA10998A (de)
PE (1)	PE109898A1 (de)
PL (1)	PL332313A1 (de)
SK (1)	SK35199A3 (de)
TR (1)	TR199900527T2 (de)
UY (1)	UY24717A1 (de)
WO (1)	WO1998011890A1 (de)
ZA (1)	ZA978359B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7119214B2 (en) *	2004-04-13	2006-10-10	Cephalon France	Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives
US20110319482A1 (en) *	2008-06-05	2011-12-29	Peter Blower	Novel treatments
US20130281524A1 (en) *	2008-06-05	2013-10-24	Peter Blower	Novel treatments
PT2464645T (pt)	2009-07-27	2017-10-11	Gilead Sciences Inc	Compostos heterocíclicos fusionados como moduladores do canal de iões
AU2010325755A1 (en) *	2009-12-03	2012-06-21	Proximagen Ltd	Treatment of infectious diseases
WO2011067608A1 (en) *	2009-12-03	2011-06-09	Minster Research Ltd	Treatment of allodynia and hyperalgesia
WO2012003392A1 (en)	2010-07-02	2012-01-05	Gilead Sciences, Inc.	Fused heterocyclic compounds as ion channel modulators
AU2012253653A1 (en)	2011-05-10	2013-05-02	Gilead Sciences, Inc.	Fused heterocyclic compounds as sodium channel modulators
NO3175985T3 (de)	2011-07-01	2018-04-28
TWI622583B (zh)	2011-07-01	2018-05-01	基利科學股份有限公司	作為離子通道調節劑之稠合雜環化合物
CN106397317B (zh) *	2016-09-26	2019-03-22	天津师范大学	1,2,3,4-四氢喹啉化合物及其合成方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9112721D0 (en) *	1991-06-13	1991-07-31	Smithkline Beecham Plc	Novel treatment
US5510375A (en) *	1993-11-19	1996-04-23	Warner-Lambert Company	Coumarin derivatives as protease inhibitors and antiviral agents
GB9411635D0 (en) *	1994-06-10	1994-08-03	Smithkline Beecham Plc	Novel treatment
ATE250052T1 (de) *	1994-06-10	2003-10-15	Smithkline Beecham Plc	Benzopyrane und deren verwendung als heilmittel

1996
- 1996-09-18 GB GBGB9619492.3A patent/GB9619492D0/en active Pending
1997
- 1997-09-15 NZ NZ334271A patent/NZ334271A/en unknown
- 1997-09-15 EA EA199900306A patent/EA199900306A1/ru unknown
- 1997-09-15 JP JP10514309A patent/JP2001500520A/ja not_active Ceased
- 1997-09-15 AU AU47047/97A patent/AU730465B2/en not_active Ceased
- 1997-09-15 HU HU9904638A patent/HUP9904638A3/hu unknown
- 1997-09-15 PL PL97332313A patent/PL332313A1/xx unknown
- 1997-09-15 AT AT97909300T patent/ATE270102T1/de not_active IP Right Cessation
- 1997-09-15 ID IDW990097A patent/ID23175A/id unknown
- 1997-09-15 CN CN97197979A patent/CN1230885A/zh active Pending
- 1997-09-15 EP EP97909300A patent/EP0939630B1/de not_active Expired - Lifetime
- 1997-09-15 TR TR1999/00527T patent/TR199900527T2/xx unknown
- 1997-09-15 DE DE69729735T patent/DE69729735T2/de not_active Expired - Fee Related
- 1997-09-15 WO PCT/EP1997/005168 patent/WO1998011890A1/en not_active Ceased
- 1997-09-15 AP APAP/P/1999/001473A patent/AP9901473A0/en unknown
- 1997-09-15 IL IL12878697A patent/IL128786A0/xx unknown
- 1997-09-15 SK SK351-99A patent/SK35199A3/sk unknown
- 1997-09-15 BR BR9712030A patent/BR9712030A/pt not_active IP Right Cessation
- 1997-09-15 ES ES97909300T patent/ES2223075T3/es not_active Expired - Lifetime
- 1997-09-15 KR KR1019997002238A patent/KR20000036184A/ko not_active Withdrawn
- 1997-09-15 CA CA002266681A patent/CA2266681A1/en not_active Abandoned
- 1997-09-16 AR ARP970104238A patent/AR008838A1/es not_active Application Discontinuation
- 1997-09-16 MA MA24799A patent/MA24321A1/fr unknown
- 1997-09-16 UY UY24717A patent/UY24717A1/es not_active Application Discontinuation
- 1997-09-16 ID IDP973201A patent/ID19542A/id unknown
- 1997-09-17 DZ DZ970161A patent/DZ2311A1/xx active
- 1997-09-17 ZA ZA978359A patent/ZA978359B/xx unknown
- 1997-09-18 PE PE1997000831A patent/PE109898A1/es not_active Application Discontinuation
1999
- 1999-03-15 BG BG103252A patent/BG103252A/xx unknown
- 1999-03-17 NO NO991292A patent/NO991292L/no not_active Application Discontinuation
- 1999-03-18 OA OA9900060A patent/OA10998A/en unknown

Also Published As

Publication number	Publication date
TR199900527T2 (xx)	1999-06-21
WO1998011890A1 (en)	1998-03-26
ZA978359B (en)	1999-03-17
CN1230885A (zh)	1999-10-06
NZ334271A (en)	2001-03-30
EP0939630A1 (de)	1999-09-08
CA2266681A1 (en)	1998-03-26
HUP9904638A3 (en)	2001-08-28
ES2223075T3 (es)	2005-02-16
AU4704797A (en)	1998-04-14
UY24717A1 (es)	2001-08-27
IL128786A0 (en)	2000-01-31
EP0939630B1 (de)	2004-06-30
AR008838A1 (es)	2000-02-23
NO991292D0 (no)	1999-03-17
DZ2311A1 (fr)	2002-12-28
NO991292L (no)	1999-03-17
HUP9904638A2 (hu)	2001-05-28
KR20000036184A (ko)	2000-06-26
PL332313A1 (en)	1999-08-30
EA199900306A1 (ru)	1999-08-26
MA24321A1 (fr)	1998-04-01
DE69729735T2 (de)	2005-07-14
AP9901473A0 (en)	1999-03-31
JP2001500520A (ja)	2001-01-16
ATE270102T1 (de)	2004-07-15
BG103252A (en)	1999-09-30
AU730465B2 (en)	2001-03-08
PE109898A1 (es)	1999-03-21
OA10998A (en)	2003-03-04
ID19542A (id)	1998-07-23
DE69729735D1 (de)	2004-08-05
BR9712030A (pt)	1999-08-24
GB9619492D0 (en)	1996-10-30
ID23175A (id)	2000-03-23

Publication	Publication Date	Title
US6589986B2 (en)	2003-07-08	Methods of treating anxiety disorders
JPH01224316A (ja)	1989-09-07	医薬製剤
CN101102757A (zh)	2008-01-09	治疗多囊性肾疾病的方法
US5466700A (en)	1995-11-14	Anesthetic use of N-phenyl-N-(4-piperidinyl)amides
EP0939630B1 (de)	2004-06-30	Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
FI120403B (fi)	2009-10-15	4-(2-amino-6-(syklopropyyliamino)-9H-purin-9-yyli)-2-syklopenteeni-1-metanoli-sukkinaatti viruksia torjuvana aineena
KR20000075896A (ko)	2000-12-26	안면 수술에서의 레보부피바카인의 용도
MX2010013312A (es)	2011-05-30	Tratamientos novedoos.
HUP0303236A2 (hu)	2004-01-28	Karbamátszármazékok alkalmazása fájdalomcsillapításra
KR20010032009A (ko)	2001-04-16	수면성 무호흡의 치료에 미타자핀을 사용하는 방법
MX2010013313A (es)	2011-05-30	Tratamientos novedosos.
KR20000049086A (ko)	2000-07-25	발기부전 치료용 피라졸리논
HUP0000756A2 (hu)	2000-10-28	Levobupivakain vagy ropivakain alkalmazása migrén kezelésére alkalmas gyógyszerkészítmények előállítására
US6492415B2 (en)	2002-12-10	Use of benzopyranols to treat neurological disorders
EP0271271A2 (de)	1988-06-15	Pharmazeutische Zubereitungen
CZ92999A3 (cs)	2000-05-17	Farmaceutický prostředek pro léčbu a/nebo profylaxi neurologických poruch a použití sloučenin obsahujících fosfor k výrobě léčiva
KR20010021796A (ko)	2001-03-15	선택성 세로토닌 재흡수 억제제 (ｓｓｒｉ)를 사용하는심장 질환의 치료 및 예방법
JP7247894B2 (ja)	2023-03-29	ＦＰ作動薬とβ遮断薬を含有する緑内障治療剤
JP4362368B2 (ja)	2009-11-11	神経因性疼痛および群発および偏頭痛に伴う疼痛の防止または処置に使用するためのカルバメート化合物
EP0971714B1 (de)	2002-10-09	Verfahren zur verwendung von cyclooxygenase-2 hemmern zur behandlung und vorbeugung der demenz
SE9401965D0 (sv)	1994-06-07	New compounds
JP2008184396A (ja)	2008-08-14	神経損傷に起因する身体機能障害の予防及び治療のための医薬
JP2003504396A (ja)	2003-02-04	マクロライド化合物の新規用途
HK40033075B (en)	2023-12-01	THERAPEUTIC AGENT FOR GLAUCOMA COMPRISING FP AGONIST AND β BLOCKER
JPS63165317A (ja)	1988-07-08	製薬生成物